X

Trial Profile

Rationale and Design of a Prospective, Multicenter Phase Ⅱ Clinical Trial of Safety and Efficacy Evaluation of Long Course Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jul 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Tislelizumab (Primary)
Indications Rectal cancer
Focus Therapeutic Use
Acronyms NCRT-PD-1-LARC trial

Most Recent Events

07 Jun 2022 Short term esults presented at the 58th Annual Meeting of the American Society of Clinical Oncology
27 Apr 2022 Results published in the BMC Cancer.
07 Feb 2022 Planned End Date changed from 1 May 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com